Selectis Health, Inc (GBCS) Fair Value & Analysis
Healthcare · US · Market cap $10.0M
Fair value as of: Jun 26, 2026
Analysis
Selectis Health, Inc (GBCS) currently trades at $5.30, while our model-based Fair Value estimate is $4.14 — implying the stock looks roughly 21.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Selectis Health, Inc. owns and operates, through wholly-owned subsidiaries Assisted Living Facilities, Independent Living Facilities, and Skilled Nursing Facilities across the South and Southeastern portions of the US. The Company acquires, develops, leases and manages healthcare real estate and provides healthcare operations through our wholly-owned subsidiaries. Our portfolio is comprised of investments in the following healthcare operations: (i) senior housing (including independent and assisted living) and (ii) post-acute/skilled nursing. We will make investments within our healthcare operations using the following six investment products: (i) direct ownership of properties, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management, (v) the Housing and Economic Recovery Act of 2008 (RIDEA), which represents investments in senior housing operations utilizing the structure permitted by RIDEA and (vi) owning healthcare operations. Selectis Health, Inc…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Selectis Health, Inc (GBCS) undervalued?
What is the fair value of GBCS?
What is the quality score of GBCS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.